{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:05:46Z","timestamp":1779318346142,"version":"3.51.4"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00508-025-02665-w","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:13:56Z","timestamp":1779315236000},"page":"289-302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Geriatrische Aspekte bei Diabetes mellitus (Update 2026)","Geriatric aspects of diabetes mellitus (Update 2026)"],"prefix":"10.1007","volume":"138","author":[{"given":"Joakim","family":"Huber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Smeikal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph H.","family":"Saely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Lechleitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2665_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-1025-0","author":"W Rathmann","year":"2003","unstructured":"Rathmann\u00a0W, Haastert\u00a0B, Icks\u00a0A, L\u00f6wel\u00a0H, Meisinger\u00a0C, Holle\u00a0R, et\u00a0al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. Kora Surv 2000 Diabetol. 2003; https:\/\/doi.org\/10.1007\/s00125-002-1025-0.","journal-title":"Kora Surv 2000 Diabetol"},{"key":"2665_CR2","doi-asserted-by":"publisher","unstructured":"The decode study group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13\u00a0European cohorts. Diabetes Care. 2003. https:\/\/doi.org\/10.2337\/diacare.26.1.61.","DOI":"10.2337\/diacare.26.1.61"},{"key":"2665_CR3","doi-asserted-by":"publisher","unstructured":"Classification and diagnosis of diabetes: Standards of medical care in Diabetesd2018. Diabetes Care. 2018; https:\/\/doi.org\/10.2337\/dc18-S002","DOI":"10.2337\/dc18-S002"},{"key":"2665_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-015-0931-3","volume-title":"Diabetes mellitus \u2013 Definition, Klassifikation und Diagnose. Wiener klinische Wochenzeitschrift","author":"M Roden","year":"2016","unstructured":"Roden\u00a0M. Diabetes mellitus \u2013 Definition, Klassifikation und Diagnose. Wiener klinische Wochenzeitschrift. 2016. https:\/\/doi.org\/10.1007\/s00508-015-0931-3."},{"key":"2665_CR5","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.2.176","author":"HE Resnick","year":"2000","unstructured":"Resnick\u00a0HE, Harris\u00a0MI, Brock\u00a0DB, Harris\u00a0TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: Results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2000; https:\/\/doi.org\/10.2337\/diacare.23.2.176.","journal-title":"Diabetes Care"},{"key":"2665_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.9.921","author":"MA Bethel","year":"2007","unstructured":"Bethel\u00a0MA, Sloan\u00a0FA, Belsky\u00a0D, Feinglos\u00a0MN. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med. 2007; https:\/\/doi.org\/10.1001\/archinte.167.9.921.","journal-title":"Arch Intern Med"},{"key":"2665_CR7","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.2.231","author":"MJ Rosenthal","year":"1998","unstructured":"Rosenthal\u00a0MJ, Fajardo\u00a0M, Gilmore\u00a0S, Morley\u00a0JE, Naliboff\u00a0BD. Hospitalization and mortality of diabetes in older adults: A\u00a03-year prospective study. Diabetes Care. 1998; https:\/\/doi.org\/10.2337\/diacare.21.2.231.","journal-title":"Diabetes Care"},{"key":"2665_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504347","author":"M Tancredi","year":"2015","unstructured":"Tancredi\u00a0M, Rosengren\u00a0A, Svensson\u00a0A\u2011M, Kosiborod\u00a0M, Pivodic\u00a0A, Gudbj\u00f6rnsdottir\u00a0S, et\u00a0al. Excess Mortality among Persons with Type\u00a02 Diabetes. N\u00a0Engl J Med. 2015; https:\/\/doi.org\/10.1056\/NEJMoa1504347.","journal-title":"N Engl J Med"},{"key":"2665_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2011.08.021.Secreted","author":"WC Knowler","year":"2002","unstructured":"Knowler\u00a0WC, Barrett-Connor\u00a0E, Fowler\u00a0SE, Hamman\u00a0RF, Lachin\u00a0JM, Walker\u00a0EA, et\u00a0al. Diabetes Prevention Program Research Group. Diabetes prevention program research group reduction in the incidence of type\u00a02 diabetes with lifestyle intervention metformin. N\u00a0Engl J Med. 2002; https:\/\/doi.org\/10.1016\/j.biotechadv.2011.08.021.Secreted.","journal-title":"N Engl J Med"},{"key":"2665_CR10","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2280","author":"BJ Jefferis","year":"2012","unstructured":"Jefferis\u00a0BJ, Lennon\u00a0L, Whincup\u00a0PH, Wannamethee\u00a0SG. Longitudinal associations between changes in physical activity and onset of type\u00a02 diabetes in older British men: The influence of adiposity. Diabetes Care. 2012; https:\/\/doi.org\/10.2337\/dc11-2280.","journal-title":"Diabetes Care"},{"key":"2665_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008234","author":"DT Villareal","year":"2011","unstructured":"Villareal\u00a0DT, Chode\u00a0S, Parimi\u00a0N, Sinacore\u00a0DR, Hilton\u00a0T, Armamento-Villareal\u00a0R, et\u00a0al. Weight Loss, Exercise, or Both and Physical Function in Obese Older Adults. N\u00a0Engl J Med. 2011; https:\/\/doi.org\/10.1056\/NEJMoa1008234.","journal-title":"N Engl J Med"},{"key":"2665_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2017.10.021","author":"GS Meneilly","year":"2018","unstructured":"Meneilly\u00a0GS, Knip\u00a0A, Miller\u00a0DB, Sherifali\u00a0D, Tessier\u00a0D, Zahedi\u00a0A. Diabetes in Older People Diabetes Canada Clinical Practice Guidelines Expert Committee. Can J Diabetes. 2018; https:\/\/doi.org\/10.1016\/j.jcjd.2017.10.021.","journal-title":"Can J Diabetes"},{"key":"2665_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jada.2010.08.022","author":"B Dorner","year":"2010","unstructured":"Dorner\u00a0B, Friedrich\u00a0EK, Posthauer\u00a0ME, American Dietetic Association. Position of the American Dietetic Association: individualized nutrition approaches for older adults in health care communities. J\u00a0Am Diet Assoc. 2010; https:\/\/doi.org\/10.1016\/j.jada.2010.08.022. [corrected] [published erratum appears in J AM DIET ASSOC 2010 Dec;110(12):1941].","journal-title":"J Am Diet Assoc"},{"key":"2665_CR14","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1343169","volume-title":"Leitlinie der Deutschen Gesellschaft f\u00fcr Ern\u00e4hrungsmedizin (DGEM) in Zusammenarbeit mit der GESKES, der AKE und der DGG. Aktuel Ernahrungsmed","author":"D Volkert","year":"2013","unstructured":"Volkert\u00a0D, Bauer\u00a0J, Fr\u00fchwald\u00a0T, Gehrke\u00a0I, Lechleitner\u00a0M, Lenzen-Gro\u00dfimlinghaus\u00a0R, et\u00a0al. Leitlinie der Deutschen Gesellschaft f\u00fcr Ern\u00e4hrungsmedizin (DGEM) in Zusammenarbeit mit der GESKES, der AKE und der DGG. Aktuel Ernahrungsmed. 2013. https:\/\/doi.org\/10.1055\/s-0033-1343169."},{"key":"2665_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.2004.10719430","author":"WJ Evans","year":"2004","unstructured":"Evans\u00a0WJ. Protein Nutrition, Exercise and Aging. J\u00a0Am Coll Nutr. 2004; https:\/\/doi.org\/10.1080\/07315724.2004.10719430.","journal-title":"J Am Coll Nutr"},{"key":"2665_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2012.04099.x","author":"RR Kalyani","year":"2012","unstructured":"Kalyani\u00a0RR, Tian\u00a0J, Xue\u00a0QL, Walston\u00a0J, Cappola\u00a0AR, Fried\u00a0LP, et\u00a0al. Hyperglycemia and incidence of frailty and lower extremity mobility limitations in older women. J\u00a0Am Geriatr Soc. 2012; https:\/\/doi.org\/10.1111\/j.1532-5415.2012.04099.x.","journal-title":"J Am Geriatr Soc"},{"key":"2665_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glv133","author":"K Bandeen-Roche","year":"2015","unstructured":"Bandeen-Roche\u00a0K, Seplaki\u00a0CL, Huang\u00a0J, Buta\u00a0B, Kalyani\u00a0RR, Varadhan\u00a0R, et\u00a0al. Frailty in Older Adults: A\u00a0Nationally Representative Profile in the United States. Journals Gerontol A Biol Sci Med Sci. 2015; https:\/\/doi.org\/10.1093\/gerona\/glv133.","journal-title":"Journals Gerontol A Biol Sci Med Sci"},{"key":"2665_CR18","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.3.471","author":"AG Bertoni","year":"2002","unstructured":"Bertoni\u00a0AG, Krop\u00a0JS, Anderson\u00a0GF, Brancati\u00a0FL. Diabetes-related morbidity and mortality in a\u00a0national sample of U.S. elders. Diabetes Care. 2002; https:\/\/doi.org\/10.2337\/diacare.25.3.471.","journal-title":"Diabetes Care"},{"key":"2665_CR19","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.9.1272","author":"EW Gregg","year":"2000","unstructured":"Gregg\u00a0EW, Beckles\u00a0GLA, Williamson\u00a0DF, Leveille\u00a0SG, Langlois\u00a0JA, Engelgau\u00a0MM, et\u00a0al. Diabetes and physical disability among older U.S. adults. Diabetes Care. 2000; https:\/\/doi.org\/10.2337\/diacare.23.9.1272.","journal-title":"Diabetes Care"},{"key":"2665_CR20","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.5.747","author":"JS Krop","year":"1998","unstructured":"Krop\u00a0JS, Powe\u00a0NR, Weller\u00a0WE, Shaffer\u00a0TJ, Saudek\u00a0CD, Anderson\u00a0GF. Patterns of expenditures and use of services among older adults with diabetes: Implications for the transition to capitated managed care. Diabetes Care. 1998; https:\/\/doi.org\/10.2337\/diacare.21.5.747.","journal-title":"Diabetes Care"},{"key":"2665_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/56.3.M146","author":"LP Fried","year":"2001","unstructured":"Fried\u00a0LP, Tangen\u00a0CM, Walston\u00a0J, Newman\u00a0AB, Hirsch\u00a0C, Gottdiener\u00a0J, et\u00a0al. Frailty in Older Adults: Evidence for a\u00a0Phenotype. J\u00a0Gerontol A Biol Sci Med Sci. 2001; https:\/\/doi.org\/10.1093\/gerona\/56.3.M146.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"2665_CR22","doi-asserted-by":"publisher","first-page":"61676","DOI":"10.1016\/S0140-6736","volume":"1","author":"A Sinclair","year":"2013","unstructured":"Sinclair\u00a0A, Morley\u00a0J. Frailty and diabetes. Lancet. 2013;1(3):61676\u201361671. https:\/\/doi.org\/10.1016\/S0140-6736.","journal-title":"Lancet"},{"key":"2665_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume-title":"Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft\u00a0AJ, Bahat\u00a0G, Bauer\u00a0J, Boirie\u00a0Y, Bruy\u00e8re\u00a0O, Cederholm\u00a0T, et\u00a0al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. Oxford University Press; 2019. S.\u00a016\u201331. https:\/\/doi.org\/10.1093\/ageing\/afy169."},{"key":"2665_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2013.02.006","author":"M Leenders","year":"2013","unstructured":"Leenders\u00a0M, Verdijk\u00a0LB, van der Hoeven\u00a0L, Adam\u00a0JJ, van Kranenburg\u00a0J, Nilwik\u00a0R, et\u00a0al. Patients with type\u00a02 diabetes show a\u00a0greater decline in muscle mass, muscle strength, and functional capacity with aging. J\u00a0Am Med Dir Assoc. 2013; https:\/\/doi.org\/10.1016\/j.jamda.2013.02.006.","journal-title":"J Am Med Dir Assoc"},{"key":"2665_CR25","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2202","author":"S Volpato","year":"2012","unstructured":"Volpato\u00a0S, Bianchi\u00a0L, Lauretani\u00a0F, Lauretani\u00a0F, Bandinelli\u00a0S, Guralnik\u00a0JM, et\u00a0al. Role of muscle mass and muscle quality in the association between diabetes and gait speed. Diabetes Care. 2012; https:\/\/doi.org\/10.2337\/dc11-2202.","journal-title":"Diabetes Care"},{"key":"2665_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2014.04.021","author":"J Woo","year":"2014","unstructured":"Woo\u00a0J, Leung\u00a0J, Morley\u00a0JE. Validating the SARC-F: A\u00a0suitable community screening tool for sarcopenia? J\u00a0Am Med Dir Assoc. 2014; https:\/\/doi.org\/10.1016\/j.jamda.2014.04.021.","journal-title":"J Am Med Dir Assoc"},{"key":"2665_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2013.03.022","author":"JE Morley","year":"2013","unstructured":"Morley\u00a0JE, Vellas\u00a0B, Abellan van Kan\u00a0G, Anker\u00a0SD, Bauer\u00a0JM, Bernabei\u00a0R, et\u00a0al. Frailty consensus: A\u00a0call to action. J\u00a0Am Med Dir Assoc. 2013; https:\/\/doi.org\/10.1016\/j.jamda.2013.03.022.","journal-title":"J Am Med Dir Assoc"},{"key":"2665_CR28","doi-asserted-by":"publisher","DOI":"10.1055\/a-0666-0820","author":"A Bahrmann","year":"2018","unstructured":"Bahrmann\u00a0A, Bahrmann\u00a0P, Baumann\u00a0J, Bauer\u00a0J, Br\u00fcckel\u00a0E, Dreyer\u00a0M, et\u00a0al. S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter: 2.\u00a0Auflage 2018 \u2013 AWMF-Register-NR. 057-017. Diabetol Stoffwechs. 2018; https:\/\/doi.org\/10.1055\/a-0666-0820.","journal-title":"Diabetol Stoffwechs"},{"key":"2665_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/0145721713514281","author":"G Pariser","year":"2014","unstructured":"Pariser\u00a0G, Hager\u00a0K, Gillette\u00a0P, Golemboski\u00a0K, Jackson\u00a0K. Active Steps for Diabetes: A\u00a0Community-Campus Partnership Addressing Frailty and Diabetes. Diabetes Educ. 2014; https:\/\/doi.org\/10.1177\/0145721713514281.","journal-title":"Diabetes Educ"},{"key":"2665_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/039463200601900404","author":"PL Gordon","year":"2006","unstructured":"Gordon\u00a0PL, Vannier\u00a0E, Hamada\u00a0K, Layne\u00a0J, Hurley\u00a0BF, Roubenoff\u00a0R, et\u00a0al. Resistance training alters cytokine gene expression in skeletal muscle of adults with type\u00a02 diabetes. Int J Immunopathol Pharmacol. 2006; https:\/\/doi.org\/10.1177\/039463200601900404.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2665_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-012-9234-4","author":"JEB Reusch","year":"2013","unstructured":"Reusch\u00a0JEB, Bridenstine\u00a0M, Regensteiner\u00a0JG. Type\u00a02 diabetes mellitus and exercise impairment. Rev Endocr Metab Disord. 2013; https:\/\/doi.org\/10.1007\/s11154-012-9234-4.","journal-title":"Rev Endocr Metab Disord"},{"key":"2665_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2013.05.021","author":"J Bauer","year":"2013","unstructured":"Bauer\u00a0J, Biolo\u00a0G, Cederholm\u00a0T, Cesari\u00a0M, Cruz-Jentoft\u00a0AJ, Morley\u00a0JE, et\u00a0al. Evidence-based recommendations for optimal dietary protein intake in older people: A\u00a0position paper from the prot-age study group. J\u00a0Am Med Dir Assoc. 2013; https:\/\/doi.org\/10.1016\/j.jamda.2013.05.021.","journal-title":"J Am Med Dir Assoc"},{"key":"2665_CR33","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1335297","volume-title":"Praxisempfehlungen DDG\/DGIM: Therapie des Typ-2-Diabetes","author":"R Landgraf","year":"2013","unstructured":"Landgraf\u00a0R, Kellerer\u00a0M, Fach\u00a0E, Gallwitz\u00a0B, Hamann\u00a0A, Joost\u00a0HG, et\u00a0al. Praxisempfehlungen DDG\/DGIM: Therapie des Typ-2-Diabetes. Diabetologie und Stoffwechsel. 2013. https:\/\/doi.org\/10.1055\/s-0033-1335297."},{"key":"2665_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427","author":"PA James","year":"2014","unstructured":"James\u00a0PA, Oparil\u00a0S, Carter\u00a0BL, Cushman\u00a0WC, Dennison-Himmelfarb\u00a0C, Handler\u00a0J, et\u00a0al. Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAMA. 2014; https:\/\/doi.org\/10.1001\/jama.2013.284427.","journal-title":"JAMA"},{"key":"2665_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12035","author":"SM Kirkman","year":"2012","unstructured":"Kirkman\u00a0SM, Briscoe\u00a0VJ, Clark\u00a0N, Florez\u00a0H, Haas\u00a0LB, Halter\u00a0JB, et\u00a0al. Diabetes in older adults: A\u00a0consensus report. J\u00a0Am Geriatr Soc. 2012; https:\/\/doi.org\/10.1111\/jgs.12035.","journal-title":"J Am Geriatr Soc"},{"key":"2665_CR36","doi-asserted-by":"publisher","unstructured":"13. Older adults: Standards of care in diabetes\u20142025. Diabetes Care. American Diabetes Association Inc.; 2025;48:S266\u201382. https:\/\/doi.org\/10.2337\/dc25-S013","DOI":"10.2337\/dc25-S013"},{"key":"2665_CR37","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S002","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Standards of Medical Care in Diabetes\u20142018. Diabetes Care. 2018; https:\/\/doi.org\/10.2337\/dc18-S002.","journal-title":"Diabetes Care"},{"key":"2665_CR38","doi-asserted-by":"publisher","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL, Koskinas\u00a0KC, Casula\u00a0M, Badimon\u00a0L, Chapman\u00a0MJ, De Backer\u00a0GG, Delgado\u00a0V, Ference\u00a0BA, Graham\u00a0IM, Halliday\u00a0A, Landmesser\u00a0U, Mihaylova\u00a0B, Pedersen\u00a0TR, Riccardi\u00a0G, Richter\u00a0DJ, Sabatine\u00a0MS, Taskinen\u00a0MR, Tokgozoglu\u00a0L, Wiklund O\u00a0ESC Scientific Document Group. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","DOI":"10.1093\/eurheartj\/ehz455"},{"issue":"42","key":"2665_CR39","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/EURHEARTJ\/EHAB484","volume":"2021","author":"FLJ Visseren","year":"2021","unstructured":"Visseren\u00a0FLJ, Mac\u00a0HF, Smulders\u00a0YM, Carballo\u00a0D, Koskinas\u00a0KC, B\u00e4ck\u00a0M, et\u00a0al. ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J Oxf Univ Press. 2021;2021(42):3227\u2013337. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB484.","journal-title":"Eur Heart J Oxf Univ Press"},{"key":"2665_CR40","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"2024","author":"CP McCarthy","year":"2024","unstructured":"McEvoy JW, McCarthy\u00a0CP, Bruno\u00a0RM, Brouwers\u00a0S, Canavan\u00a0MD, Ceconi\u00a0C, Christodorescu\u00a0RM, et\u00a0al. ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J Oxf Univ Press. 2024;2024:3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J Oxf Univ Press"},{"key":"2665_CR41","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0737","author":"AM Rawlings","year":"2014","unstructured":"Rawlings\u00a0AM, Sharrett\u00a0AR, Schneider\u00a0ALC, Coresh\u00a0J, Albert\u00a0M, Couper\u00a0D, et\u00a0al. Diabetes in midlife and cognitive change over 20\u00a0years: A\u00a0cohort study. Ann Intern Med. 2014; https:\/\/doi.org\/10.7326\/M14-0737.","journal-title":"Ann Intern Med"},{"key":"2665_CR42","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160114","author":"W Li","year":"2016","unstructured":"Li\u00a0W, Huang\u00a0E. An Update on Type\u00a02 Diabetes Mellitus as a\u00a0Risk Factor for Dementia. J\u00a0Alzheimer\u2019s Dis. 2016; https:\/\/doi.org\/10.3233\/JAD-160114.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2665_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.1117","author":"K Yaffe","year":"2012","unstructured":"Yaffe\u00a0K, Falvey\u00a0C, Hamilton\u00a0N, Schwartz\u00a0AV, Simonsick\u00a0EM, Satterfield\u00a0S, et\u00a0al. Diabetes, glucose control, and 9\u2011year cognitive decline among older adults without dementia. Arch Neurol. 2012; https:\/\/doi.org\/10.1001\/archneurol.2012.1117.","journal-title":"Arch Neurol"},{"key":"2665_CR44","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.2337\/DC20-2850","volume":"44","author":"B Zheng","year":"2021","unstructured":"Zheng\u00a0B, Su\u00a0B, Price\u00a0G, Tzoulaki\u00a0I, Ahmadi-Abhari\u00a0S, Middleton\u00a0L. Glycemic Control, Diabetic Complications, and Risk of Dementia in Patients With Diabetes: Results From a\u00a0Large U.K. Cohort Study. Diabetes Care Am Diabetes Assoc. 2021;44:1556\u201363. https:\/\/doi.org\/10.2337\/DC20-2850.","journal-title":"Diabetes Care Am Diabetes Assoc"},{"key":"2665_CR45","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.2337\/DC21-0149","volume":"44","author":"ACE van Gennip","year":"2021","unstructured":"van Gennip\u00a0ACE, Stehouwer\u00a0CDA, van Boxtel\u00a0MPJ, Verhey\u00a0FRJ, Koster\u00a0A, Kroon\u00a0AA, et\u00a0al. Association of Type\u00a02 Diabetes, According to the Number of Risk Factors Within Target Range, With Structural Brain Abnormalities, Cognitive Performance, and Risk of Dementia. Diabetes Care Am Diabetes Assoc. 2021;44:2493\u2013502. https:\/\/doi.org\/10.2337\/DC21-0149.","journal-title":"Diabetes Care Am Diabetes Assoc"},{"key":"2665_CR46","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.23.3095","author":"RC Kessler","year":"2003","unstructured":"Kessler\u00a0RC, Berglund\u00a0P, Demler\u00a0O, Jin\u00a0R, Koretz\u00a0D, Merikangas\u00a0KR, et\u00a0al. The Epidemiology of Major Depressive Disorder: Results from the National Comorbidity Survey Replication (NCS-R). J\u00a0Am Med Assoc. 2003; https:\/\/doi.org\/10.1001\/jama.289.23.3095.","journal-title":"J Am Med Assoc"},{"key":"2665_CR47","unstructured":"W. K, H.S. P, A.R. R, M. F\u2011G, D. D, F.B. W. Effect of depression and diabetes mellitus on the risk for dementia: A\u00a0national population-based cohort study. JAMA Psychiatry. 2015."},{"key":"2665_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057058","author":"FEP van Dooren","year":"2013","unstructured":"van Dooren\u00a0FEP, Nefs\u00a0G, Schram\u00a0MT, Verhey\u00a0FRJ, Denollet\u00a0J, Pouwer\u00a0F. Depression and Risk of Mortality in People with Diabetes Mellitus: A\u00a0Systematic Review and Meta-Analysis. Plos One. 2013; https:\/\/doi.org\/10.1371\/journal.pone.0057058.","journal-title":"Plos One"},{"key":"2665_CR49","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.10.2822","author":"SA Black","year":"2003","unstructured":"Black\u00a0SA, Markides\u00a0KS, Ray\u00a0LA. Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type\u00a02 diabetes. Diabetes Care. 2003; https:\/\/doi.org\/10.2337\/diacare.26.10.2822.","journal-title":"Diabetes Care"},{"key":"2665_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12833","author":"LB Kimbro","year":"2014","unstructured":"Kimbro\u00a0LB, Mangione\u00a0CM, Steers\u00a0WN, Duru\u00a0OK, McEwen\u00a0L, Karter\u00a0A, et\u00a0al. Depression and all-cause mortality in persons with diabetes mellitus: Are older adults at higher risk? Results from the translating research into action for diabetes study. J\u00a0Am Geriatr Soc. 2014; https:\/\/doi.org\/10.1111\/jgs.12833.","journal-title":"J Am Geriatr Soc"},{"key":"2665_CR51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2337\/DC22-S013","volume":"45","author":"ADAPP Committee","year":"2022","unstructured":"Committee\u00a0ADAPP. 13. Older Adults: Standards of Medical Care in Diabetes\u20142022. Diabetes Care. Am Diabetes Assoc. 2022;45:195\u2013207. https:\/\/doi.org\/10.2337\/DC22-S013.","journal-title":"Am Diabetes Assoc"},{"issue":"5","key":"2665_CR52","doi-asserted-by":"publisher","first-page":"90026","DOI":"10.1016\/0022-3956","volume":"7","author":"MF Folstein","year":"1975","unstructured":"Folstein\u00a0MF, Folstein\u00a0SE, McHugh\u00a0PR. \u201eMini-mental state\u201c. A\u00a0practical method for grading the cognitive state of patients for the clinician. J\u00a0Psychiatr Res Elsevier Ltd. 1975;7(5):90026\u201390026. https:\/\/doi.org\/10.1016\/0022-3956.","journal-title":"J Psychiatr Res Elsevier Ltd"},{"key":"2665_CR53","doi-asserted-by":"publisher","unstructured":"Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a\u00a0Screen for Dementia: Validation in a\u00a0Population-Based Sample. https:\/\/doi.org\/10.1046\/j.1532-5415.2003.51465.x.","DOI":"10.1046\/j.1532-5415.2003.51465.x"},{"key":"2665_CR54","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/J.1532-5415.2005.53221.X","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine\u00a0ZS, Phillips\u00a0NA, B\u00e9dirian\u00a0V, Charbonneau\u00a0S, Whitehead\u00a0V, Collin\u00a0I, et\u00a0al. The Montreal Cognitive Assessment, MoCA: A\u00a0brief screening tool for mild cognitive impairment. J\u00a0Am Geriatr Soc. 2005;53:695\u20139. https:\/\/doi.org\/10.1111\/J.1532-5415.2005.53221.X. Blackwell Publishing Inc.;.","journal-title":"J Am Geriatr Soc"},{"key":"2665_CR55","unstructured":"Psychological Association A. APA | Guidelines for the Evaluation of Dementia and Age-Related Cognitive Change I APA task force on the evaluation of dementia and age-related cognitive change approved by APA council of representatives february 2021. 2021;"},{"key":"2665_CR56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1054773820906667","volume-title":"Age-Friendly Health Systems: The 4Ms Framework. Clin Nurs Res","author":"PZ Cacchione","year":"2020","unstructured":"Cacchione\u00a0PZ. Age-Friendly Health Systems: The 4Ms Framework. Clin Nurs Res. SAGE Publications Inc; 2020. S.\u00a0139\u201340. https:\/\/doi.org\/10.1177\/1054773820906667."},{"key":"2665_CR57","doi-asserted-by":"publisher","first-page":"E3071","DOI":"10.1073\/pnas.1514968113","volume":"113","author":"MK McClintock","year":"2016","unstructured":"McClintock\u00a0MK, Dale\u00a0W, Laumann\u00a0EO, Waite\u00a0L. Empirical redefinition of comprehensive health and well-being in the older adults of the United States. Proc Natl Acad Sci U S A Natl Acad Sci. 2016;113:E3071\u201380. https:\/\/doi.org\/10.1073\/pnas.1514968113.","journal-title":"Proc Natl Acad Sci U S A Natl Acad Sci"},{"key":"2665_CR58","doi-asserted-by":"publisher","DOI":"10.5888\/pcd9.110287","author":"N Laiteerapong","year":"2012","unstructured":"Laiteerapong\u00a0N, Iveniuk\u00a0J, John\u00a0PM, Laumann\u00a0EO, Huang\u00a0ES. Classification of Older Adults Who Have Diabetes by Comorbid Conditions, United States, 2005\u20132006. Prev Chronic Dis. 2012; https:\/\/doi.org\/10.5888\/pcd9.110287.","journal-title":"Prev Chronic Dis"},{"key":"2665_CR59","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181ca4035","volume-title":"Clinical Complexity in Middle-Aged and Older Adults With Diabetes: The Health and Retirement Study","author":"CS Blaum","year":"2010","unstructured":"Blaum\u00a0CS, Cigolle\u00a0CT, Boyd\u00a0C, Wolff\u00a0JL, Tian\u00a0Z, Langa\u00a0KM, et\u00a0al. Clinical Complexity in Middle-Aged and Older Adults With Diabetes: The Health and Retirement Study. 2010."},{"key":"2665_CR60","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/j.1532-5415.2012.04052.x","volume":"60","author":"TH Puar","year":"2012","unstructured":"Puar\u00a0TH, Khoo\u00a0JJ, Cho\u00a0LW, Xu\u00a0Y, Chen\u00a0YT, Chuo\u00a0AM, et\u00a0al. Association between glycemic control and hip fracture. J\u00a0Am Geriatr Soc. 2012;60:1493\u20137. https:\/\/doi.org\/10.1111\/j.1532-5415.2012.04052.x.","journal-title":"J Am Geriatr Soc"},{"key":"2665_CR61","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2337\/dc13-1384","volume":"37","author":"I Feinkohl","year":"2014","unstructured":"Feinkohl\u00a0I, Aung\u00a0PP, Keller\u00a0M, Robertson\u00a0CM, Morling\u00a0JR, McLachlan\u00a0S, et\u00a0al. Severe hypoglycemia and cognitive decline in older people with type\u00a02 diabetes: The edinburgh type\u00a02 diabetes study. Diabetes Care. 2014;37:507\u201315. https:\/\/doi.org\/10.2337\/dc13-1384.","journal-title":"Diabetes Care"},{"key":"2665_CR62","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2377","volume-title":"Glycemic control, complications, and death in older diabetic patients: The diabetes and aging study. Diabetes Care","author":"ES Huang","year":"2011","unstructured":"Huang\u00a0ES, Liu\u00a0JY, Moffet\u00a0HH, John\u00a0PM, Karter\u00a0AJ. Glycemic control, complications, and death in older diabetic patients: The diabetes and aging study. Diabetes Care. 2011. https:\/\/doi.org\/10.2337\/dc10-2377."},{"key":"2665_CR63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743","author":"HC Gerstein","year":"2008","unstructured":"Gerstein\u00a0HC, Miller\u00a0ME, Byington\u00a0RP, Goff\u00a0DC, Bigger\u00a0JT, Buse\u00a0JB, et\u00a0al. Effects of intensive glucose lowering in type\u00a02 diabetes. (ACCORD Study Results). N\u00a0Engl J Med. 2008; https:\/\/doi.org\/10.1056\/NEJMoa0802743.","journal-title":"N Engl J Med"},{"key":"2665_CR64","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.12.2797","author":"HH Tan","year":"2004","unstructured":"Tan\u00a0HH, McAlpine\u00a0RR, James\u00a0P, Thompson\u00a0P, McMurdo\u00a0MET, Morris\u00a0AD, et\u00a0al. Diagnosis of type\u00a02 diabetes at an older age: Effect on mortality in men and women. Diabetes Care. 2004; https:\/\/doi.org\/10.2337\/diacare.27.12.2797.","journal-title":"Diabetes Care"},{"key":"2665_CR65","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000224760.22802.e8","author":"AM Abbatecola","year":"2006","unstructured":"Abbatecola\u00a0AM, Rizzo\u00a0MR, Barbieri\u00a0M, Grella\u00a0R, Arciello\u00a0A, Laieta\u00a0MT, et\u00a0al. Postprandial plasma glucose excursions and cognitive functioning in aged type\u00a02 diabetics. Neurology. 2006; https:\/\/doi.org\/10.1212\/01.wnl.0000224760.22802.e8.","journal-title":"Neurology"},{"key":"2665_CR66","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0114","author":"JP Bremer","year":"2009","unstructured":"Bremer\u00a0JP, Jauch-Chara\u00a0K, Hallschmid\u00a0M, Schmid\u00a0S, Schultes\u00a0B. Hypoglycemia unawareness in older compared with middle-aged patients with type\u00a02 diabetes. Diabetes Care. 2009; https:\/\/doi.org\/10.2337\/dc09-0114.","journal-title":"Diabetes Care"},{"key":"2665_CR67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.460","author":"RA Whitmer","year":"2009","unstructured":"Whitmer\u00a0RA, Karter\u00a0AJ, Yaffe\u00a0K, Quesenberry\u00a0CP, Selby\u00a0JV. Hypoglycemic episodes and risk of dementia in older patients with type\u00a02 diabetes mellitus. Jama\u2014journal Am Med Assoc. 2009; https:\/\/doi.org\/10.1001\/jama.2009.460.","journal-title":"Jama\u2014journal Am Med Assoc"},{"key":"2665_CR68","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1855","author":"Z Punthakee","year":"2012","unstructured":"Punthakee\u00a0Z, Miller\u00a0ME, Launer\u00a0LJ, Williamson\u00a0JD, Lazar\u00a0RM, Cukierman-Yaffee\u00a0T, et\u00a0al. Poor cognitive function and risk of severe hypoglycemia in type\u00a02 diabetes: Post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care. 2012; https:\/\/doi.org\/10.2337\/dc11-1855.","journal-title":"Diabetes Care"},{"issue":"2","key":"2665_CR69","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.289.19.2560","volume":"290","author":"AV Chobanian","year":"2003","unstructured":"Chobanian\u00a0AV, Bakris\u00a0GL, Black\u00a0HR, Cushman\u00a0WC, Green\u00a0LA, Izzo\u00a0JL Jr., et\u00a0al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.[see comment][erratum appears in JAMA. JAMA. 2003;290(2):2003. https:\/\/doi.org\/10.1001\/jama.289.19.2560. 197.","journal-title":"JAMA"},{"key":"2665_CR70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801369","author":"NS Beckett","year":"2008","unstructured":"Beckett\u00a0NS, Peters\u00a0R, Fletcher\u00a0AE, Staessen\u00a0JA, Liu\u00a0L, Dumitrascu\u00a0D, et\u00a0al. (HyVET) Treatment of hypertension in patients 80\u00a0years of age and older. N\u00a0Engl J Med. 2008; https:\/\/doi.org\/10.1056\/NEJMoa0801369.","journal-title":"N Engl J Med"},{"key":"2665_CR71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939","author":"JT Wright","year":"2015","unstructured":"Wright\u00a0JT, Williamson\u00a0JD, Whelton\u00a0PSK, Snyder\u00a0JK, Sink\u00a0KM, Rocco\u00a0MV, et\u00a0al. SPRINT (2015; NEJM) BP targets in high-risk patients. N\u00a0Engl J Med. 2015; https:\/\/doi.org\/10.1056\/NEJMoa1511939.","journal-title":"N Engl J Med"},{"key":"2665_CR72","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","volume":"398","author":"K Rahimi","year":"2021","unstructured":"Rahimi\u00a0K, Bidel\u00a0Z, Nazarzadeh\u00a0M, Copland\u00a0E, Canoy\u00a0D, Wamil\u00a0M, et\u00a0al. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet Elsevier. 2021;398:1053\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(21)01921-8.","journal-title":"Lancet Elsevier"},{"key":"2665_CR73","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339","author":"B Williams","year":"2018","unstructured":"Williams\u00a0B, Mancia\u00a0G, Spiering\u00a0W, Rosei\u00a0EA, Azizi\u00a0M, Burnier\u00a0M, et\u00a0al. ESC\/ESH Guidelines for themanagement of arterial hypertension. Eur Heart\u00a0J. 2018; https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"},{"key":"2665_CR74","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2012.13574","author":"HH Sch\u00e4fer","year":"2012","unstructured":"Sch\u00e4fer\u00a0HH, De Villiers\u00a0JN, Sudano\u00a0I, Dischinger\u00a0S, Theus\u00a0GR, Zilla\u00a0P, et\u00a0al. Recommendations for the treatment of hypertension in the elderly and very elderly\u2014A scotoma within international guidelines. Swiss Med Wkly. 2012; https:\/\/doi.org\/10.4414\/smw.2012.13574.","journal-title":"Swiss Med Wkly"},{"key":"2665_CR75","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw272","author":"AL Catapano","year":"2016","unstructured":"Catapano\u00a0AL, Graham\u00a0I, De Backer\u00a0G, Wiklund\u00a0O, Chapman\u00a0MJ, Drexel\u00a0H, et\u00a0al. ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart\u00a0J. 2016; https:\/\/doi.org\/10.1093\/eurheartj\/ehw272.","journal-title":"Eur Heart J"},{"issue":"44","key":"2665_CR76","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"2023","author":"N Marx","year":"2023","unstructured":"Marx\u00a0N, Federici\u00a0M, Sch\u00fctt\u00a0K, M\u00fcller-Wieland\u00a0D, Ajjan\u00a0RA, Antunes\u00a0MJ, et\u00a0al. ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J Oxf Univ Press. 2023;2023(44):4043\u2013140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192.","journal-title":"Eur Heart J Oxf Univ Press"},{"key":"2665_CR77","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf190","author":"F Mach","year":"2025","unstructured":"Mach\u00a0F, Koskinas\u00a0KC, Roeters van Lennep\u00a0JE, Tokg\u00f6zo\u011flu\u00a0L, Badimon\u00a0L, Baigent\u00a0C, et\u00a0al. Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J [internet]. 2025; https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","journal-title":"Eur Heart J [internet]"},{"key":"2665_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09327-3","author":"R Collins","year":"2002","unstructured":"Collins\u00a0R, Armitage\u00a0J, Parish\u00a0S, Sleight\u00a0P, Peto\u00a0R. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A\u00a0randomised placebo-controlled trial. Lancet. 2002; https:\/\/doi.org\/10.1016\/S0140-6736(02)09327-3.","journal-title":"Lancet"},{"key":"2665_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11600-X","author":"J Shepherd","year":"2002","unstructured":"Shepherd\u00a0J, Blauw\u00a0GJ, Murphy\u00a0MB, Bollen\u00a0ELEM, Buckley\u00a0BM, Cobbe\u00a0SM, et\u00a0al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A\u00a0randomised controlled trial. Lancet. 2002; https:\/\/doi.org\/10.1016\/S0140-6736(02)11600-X.","journal-title":"Lancet"},{"key":"2665_CR80","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1671-5411.2013.02.012","author":"D Forman","year":"2013","unstructured":"Forman\u00a0D, Wenger\u00a0NK. What do the recent American Heart Association\/American College of Cardiology Foundation Clinical Practice Guidelines tell us about the evolving management of coronary heart disease in older adults? J\u00a0Geriatr Cardiol. 2013; https:\/\/doi.org\/10.3969\/j.issn.1671-5411.2013.02.012.","journal-title":"J Geriatr Cardiol"},{"key":"2665_CR81","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","volume":"396","author":"B Gencer","year":"2020","unstructured":"Gencer\u00a0B, Marston\u00a0NA, Im\u00a0KA, Cannon\u00a0CP, Sever\u00a0P, Keech\u00a0A, et\u00a0al. Efficacy and safety of lowering LDL cholesterol in older patients: a\u00a0systematic review and meta-analysis of randomised controlled trials. Lancet Elsevier. 2020;396:1637\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(20)32332-1.","journal-title":"Lancet Elsevier"},{"key":"2665_CR82","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2002.00689.x","author":"PT Donnan","year":"2002","unstructured":"Donnan\u00a0PT, MacDonald\u00a0TM, Morris\u00a0AD. Adherence to prescribed oral hypoglycaemic medication in a\u00a0population of patients with Type\u00a02 diabetes: A\u00a0retrospective cohort study. Diabet Med. 2002; https:\/\/doi.org\/10.1046\/j.1464-5491.2002.00689.x.","journal-title":"Diabet Med"},{"key":"2665_CR83","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2361","author":"KJ Lipska","year":"2011","unstructured":"Lipska\u00a0KJ, Bailey\u00a0CJ, Inzucchi\u00a0SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011; https:\/\/doi.org\/10.2337\/dc10-2361.","journal-title":"Diabetes Care"},{"key":"2665_CR84","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3460-0","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi\u00a0SE, Bergenstal\u00a0RM, Buse\u00a0JB, Diamant\u00a0M, Ferrannini\u00a0E, Nauck\u00a0M, et\u00a0al. Management of hyperglycaemia in type\u00a02 diabetes, 2015: a\u00a0patient-centred approach. Diabetologia. 2015; https:\/\/doi.org\/10.1007\/s00125-014-3460-0.","journal-title":"Diabetologia"},{"key":"2665_CR85","doi-asserted-by":"publisher","DOI":"10.4158\/EP11009.OR","author":"E Kos","year":"2012","unstructured":"Kos\u00a0E, Liszek\u00a0M, Emanuele\u00a0M, Durazo-Arvizu\u00a0R, Camacho\u00a0P. Effect of Metformin Therapy on Vitamin\u00a0D and Vitamin\u00a0B 12 Levels in Patients with Type\u00a02 Diabetes Mellitus. Endocr Pract. 2012; https:\/\/doi.org\/10.4158\/EP11009.OR.","journal-title":"Endocr Pract"},{"key":"2665_CR86","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2181","author":"J De Jager","year":"2010","unstructured":"De Jager\u00a0J, Kooy\u00a0A, Lehert\u00a0P, Wulffel\u00e9\u00a0MG, Van Der Kolk\u00a0J, Bets\u00a0D, et\u00a0al. Long term treatment with metformin in patients with type\u00a02 diabetes and risk of vitamin\u00a0B-12 deficiency: Randomised placebo controlled trial. Bmj (online). 2010; https:\/\/doi.org\/10.1136\/bmj.c2181.","journal-title":"Bmj (online)"},{"key":"2665_CR87","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.18.1975","author":"RZW Ting","year":"2006","unstructured":"Ting\u00a0RZW, Szeto\u00a0CC, Chan\u00a0MHM, Ma\u00a0KK, Chow\u00a0KM. Risk factors of vitamin B12deficiency in patients receiving metformin. Arch Intern Med. 2006; https:\/\/doi.org\/10.1001\/archinte.166.18.1975.","journal-title":"Arch Intern Med"},{"key":"2665_CR88","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3754","author":"VR Aroda","year":"2016","unstructured":"Aroda\u00a0VR, Edelstein\u00a0SL, Goldberg\u00a0RB, Knowler\u00a0WC, Marcovina\u00a0SM, Orchard\u00a0TJ, et\u00a0al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J\u00a0Clin Endocrinol Metab. 2016; https:\/\/doi.org\/10.1210\/jc.2015-3754.","journal-title":"J Clin Endocrinol Metab"},{"key":"2665_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2017.11.001","author":"M Out","year":"2018","unstructured":"Out\u00a0M, Kooy\u00a0A, Lehert\u00a0P, Schalkwijk\u00a0CA, Stehouwer\u00a0CDA. Long-term treatment with metformin in type\u00a02 diabetes and methylmalonic acid: Post hoc analysis of a\u00a0randomized controlled 4.3\u00a0year trial. J\u00a0Diabetes Complications. 2018; https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.11.001.","journal-title":"J Diabetes Complications"},{"key":"2665_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.243","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini\u00a0E, Solini\u00a0A. SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects. Nat Rev Endocrinol. 2012; https:\/\/doi.org\/10.1038\/nrendo.2011.243.","journal-title":"Nat Rev Endocrinol"},{"key":"2665_CR91","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033","author":"MJ Davies","year":"2018","unstructured":"Davies\u00a0MJ, D\u2019Alessio\u00a0DA, Fradkin\u00a0J, Kernan\u00a0WN, Mathieu\u00a0C, Mingrone\u00a0G, et\u00a0al. Management of hyperglycaemia in type\u00a02 diabetes, 2018. A\u00a0consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018; https:\/\/doi.org\/10.2337\/dci18-0033.","journal-title":"Diabetologia"},{"key":"2665_CR92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","author":"B Zinman","year":"2015","unstructured":"Zinman\u00a0B, Wanner\u00a0C, Lachin\u00a0JM, Fitchett\u00a0D, Bluhmki\u00a0E, Hantel\u00a0S, et\u00a0al. EMPA-REG. N\u00a0Engl J Med. 2015; https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"key":"2665_CR93","doi-asserted-by":"publisher","unstructured":"Canagliflozin and Cardiovascular and Renal Events in Type\u00a02 Diabetes. New England Journal of Medicine. New England Journal of Medicine (NEJM\/MMS); 2017;377:2097\u20139. https:\/\/doi.org\/10.1056\/NEJMC1712572","DOI":"10.1056\/NEJMC1712572"},{"key":"2665_CR94","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMOA1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott\u00a0SD, Raz\u00a0I, Bonaca\u00a0MP, Mosenzon\u00a0O, Kato\u00a0ET, Cahn\u00a0A, et\u00a0al. Dapagliflozin and Cardiovascular Outcomes in Type\u00a02 Diabetes. N\u00a0Engl J Med Mass Med Soc. 2019;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMOA1812389.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"2665_CR95","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMOA1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, Solomon\u00a0SD, Inzucchi\u00a0SE, K\u00f8ber\u00a0L, Kosiborod\u00a0MN, Martinez\u00a0FA, et\u00a0al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N\u00a0Engl J Med. 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMOA1911303.","journal-title":"N Engl J Med"},{"key":"2665_CR96","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMOA2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker\u00a0SD, Butler\u00a0J, Filippatos\u00a0G, Ferreira\u00a0JP, Bocchi\u00a0E, B\u00f6hm\u00a0M, et\u00a0al. Empagliflozin in Heart Failure with a\u00a0Preserved Ejection Fraction. N\u00a0Engl J Med Mass Med Soc. 2021;385:1451\u201361. https:\/\/doi.org\/10.1056\/NEJMOA2107038.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"2665_CR97","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMOA2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M, Anker\u00a0SD, Butler\u00a0J, Filippatos\u00a0G, Pocock\u00a0SJ, Carson\u00a0P, et\u00a0al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N\u00a0Engl J Med Mass Med Soc. 2020;383:1413\u201324. https:\/\/doi.org\/10.1056\/NEJMOA2022190.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"2665_CR98","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0V, Correa-Rotter\u00a0R, Chertow\u00a0GM, Greene\u00a0T, Hou\u00a0F\u2011F, et\u00a0al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD study). Mass Med Soc. 2020;383:1436\u201382. https:\/\/doi.org\/10.1056\/NEJMoa2024816. rcpi-live-cdn.s3.amazonaws.com.","journal-title":"Mass Med Soc"},{"key":"2665_CR99","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic\u00a0V, Jardine\u00a0MJ, Neal\u00a0B, Bompoint\u00a0S, Heerspink\u00a0HJ, Charytan\u00a0DM, et\u00a0al. Canagliflozin and Renal Outcomes in Type\u00a02 Diabetes and Nephropathy (CREDENCE trial). Mass Med Soc. 2019;380:2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744. rcpi-live-cdn.s3.amazonaws.com.","journal-title":"Mass Med Soc"},{"key":"2665_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2022.04.040","volume":"80","author":"M B\u00f6hm","year":"2022","unstructured":"B\u00f6hm\u00a0M, Butler\u00a0J, Filippatos\u00a0G, Ferreira\u00a0JP, Pocock\u00a0SJ, Abdin\u00a0A, et\u00a0al. Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. J\u00a0Am Coll Cardiol Elsevier Inc. 2022;80:1\u201318. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.040.","journal-title":"J Am Coll Cardiol Elsevier Inc"},{"key":"2665_CR101","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/ejhf.2707","volume":"24","author":"G Filippatos","year":"2022","unstructured":"Filippatos\u00a0G, Anker\u00a0SD, Butler\u00a0J, Farmakis\u00a0D, Ferreira\u00a0JP, Gollop\u00a0ND, et\u00a0al. Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a\u00a0secondary analysis of EMPEROR-Reduced. Eur J Heart Fail John Wiley Sons Ltd. 2022;24:2297\u2013304. https:\/\/doi.org\/10.1002\/ejhf.2707.","journal-title":"Eur J Heart Fail John Wiley Sons Ltd"},{"key":"2665_CR102","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2215\/CJN.0000000000000498","volume":"19","author":"KJ Mayne","year":"2024","unstructured":"Mayne\u00a0KJ, Sardell\u00a0RJ, Staplin\u00a0N, Judge\u00a0PK, Zhu\u00a0D, Sammons\u00a0E, et\u00a0al. Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial. Clin J Am Soc Nephrol Lippincott Williams Wilkins. 2024;19:1119\u201329. https:\/\/doi.org\/10.2215\/CJN.0000000000000498.","journal-title":"Clin J Am Soc Nephrol Lippincott Williams Wilkins"},{"key":"2665_CR103","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12244","author":"M Monami","year":"2014","unstructured":"Monami\u00a0M, Nardini\u00a0C, Mannucci\u00a0E. Efficacy and safety of sodium glucose co-transport-2\u00a0inhibitors in type\u00a02 diabetes: A\u00a0meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014; https:\/\/doi.org\/10.1111\/dom.12244.","journal-title":"Diabetes Obes Metab"},{"key":"2665_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.04.012","author":"KM Johnsson","year":"2013","unstructured":"Johnsson\u00a0KM, Ptaszynska\u00a0A, Schmitz\u00a0B, Sugg\u00a0J, Parikh\u00a0SJ, List\u00a0JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J\u00a0Diabetes Complications. 2013; https:\/\/doi.org\/10.1016\/j.jdiacomp.2013.04.012.","journal-title":"J Diabetes Complications"},{"key":"2665_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.05.004","author":"KM Johnsson","year":"2013","unstructured":"Johnsson\u00a0KM, Ptaszynska\u00a0A, Schmitz\u00a0B, Sugg\u00a0J, Parikh\u00a0SJ, List\u00a0JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J\u00a0Diabetes Complications. 2013; https:\/\/doi.org\/10.1016\/j.jdiacomp.2013.05.004.","journal-title":"J Diabetes Complications"},{"key":"2665_CR106","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.890925","author":"P Nyirjesy","year":"2014","unstructured":"Nyirjesy\u00a0P, Sobel\u00a0JD, Fung\u00a0A, Mayer\u00a0C, Capuano\u00a0G, Ways\u00a0K, et\u00a0al. Genital mycotic infections with canagliflozin, a\u00a0sodium glucose co-transporter 2 inhibitor, in patients with type\u00a02 diabetes mellitus: a\u00a0pooled analysis of clinical studies. Curr Med Res Opin. 2014; https:\/\/doi.org\/10.1185\/03007995.2014.890925.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2665_CR107","doi-asserted-by":"publisher","first-page":"60683","DOI":"10.1016\/S0140-6736","volume":"1","author":"WT Cefalu","year":"2013","unstructured":"Cefalu\u00a0WT, Leiter\u00a0LA, Yoon\u00a0KH, Arias\u00a0P, Niskanen\u00a0L, Xie\u00a0J, et\u00a0al. Efficacy and safety of canagliflozin versus glimepiride in patients with type\u00a02 diabetes inadequately controlled with metformin (CANTATA-SU): 52\u00a0week results from a\u00a0randomised, double-blind, phase\u00a03 non-inferiority trial. Lancet. 2013;1(3):60683\u201360682. https:\/\/doi.org\/10.1016\/S0140-6736.","journal-title":"Lancet"},{"key":"2665_CR108","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2491","author":"G Schernthaner","year":"2013","unstructured":"Schernthaner\u00a0G, Gross\u00a0JL, Rosenstock\u00a0J, Guarisco\u00a0M, Fu\u00a0M, Yee\u00a0J, et\u00a0al. Canagliflozin compared with sitagliptin for patients with type\u00a02 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A\u00a052-week randomized trial. Diabetes Care. 2013; https:\/\/doi.org\/10.2337\/dc12-2491.","journal-title":"Diabetes Care"},{"key":"2665_CR109","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00007","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou\u00a0D, Karagiannis\u00a0T, Athanasiadou\u00a0E, Mainou\u00a0M, Liakos\u00a0A, Bekiari\u00a0E, et\u00a0al. Sodium-glucose cotransporter 2\u00a0inhibitors for type\u00a02 diabetes: A\u00a0systematic review and meta-analysis. Ann Intern Med. 2013; https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00007.","journal-title":"Ann Intern Med"},{"key":"2665_CR110","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamasurg.2025.0940","volume":"160","author":"RT Tallarico","year":"2025","unstructured":"Tallarico\u00a0RT, Jing\u00a0B, Lu\u00a0K, Chawla\u00a0SA, Luo\u00a0Y, Badathala\u00a0A, et\u00a0al. Postoperative Outcomes among Sodium-Glucose Cotransporter 2 Inhibitor Users. Jama Surg Am Med Assoc. 2025;160:681\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2025.0940.","journal-title":"Jama Surg Am Med Assoc"},{"key":"2665_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5","author":"DJ Drucker","year":"2006","unstructured":"Drucker\u00a0DJ, Nauck\u00a0MA. The incretin system: glucagon-like peptide\u20111 receptor agonists and dipeptidyl peptidase-4\u00a0inhibitors in type\u00a02 diabetes. Lancet. 2006; https:\/\/doi.org\/10.1016\/S0140-6736(06)69705-5.","journal-title":"Lancet"},{"key":"2665_CR112","doi-asserted-by":"publisher","unstructured":"10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes\u20142022. Am Diabetes Assoc. 2021; https:\/\/doi.org\/10.2337\/dc22-S010","DOI":"10.2337\/dc22-S010"},{"key":"2665_CR113","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.cmet.2025.07.004","volume-title":"Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice","author":"T Karasawa","year":"2025","unstructured":"Karasawa\u00a0T, Choi\u00a0RH, Meza\u00a0CA, Rout\u00a0S, Drummond\u00a0MJ, Chaix\u00a0A, et\u00a0al. Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice. Cell Metab. Cell Press; 2025. S.\u00a01619\u201320. https:\/\/doi.org\/10.1016\/j.cmet.2025.07.004."},{"key":"2665_CR114","doi-asserted-by":"publisher","DOI":"10.1055\/a-2582-5787","author":"S Engeli","year":"2025","unstructured":"Engeli\u00a0S, St\u00fcdemann\u00a0S. Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im h\u00f6heren Lebensalter geeignet? Diabetol Stoffwechs [internet]. 2025; https:\/\/doi.org\/10.1055\/a-2582-5787.","journal-title":"Diabetol Stoffwechs [internet]"},{"key":"2665_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108783","author":"A Bilal","year":"2024","unstructured":"Bilal\u00a0A, Yi\u00a0F, Gonzalez\u00a0GR, Ali\u00a0M, Im\u00a0KA, Ruff\u00a0CT, et\u00a0al. Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: Systematic review and meta-analysis. J\u00a0Diabetes Complicat Elsevier Inc. 2024; https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108783.","journal-title":"J Diabetes Complicat Elsevier Inc"},{"key":"2665_CR116","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0360","author":"A Seminer","year":"2025","unstructured":"Seminer\u00a0A, Mulihano\u00a0A, O\u2019Brien\u00a0C, Krewer\u00a0F, Costello\u00a0M, Judge\u00a0C, et\u00a0al. Cardioprotective Glucose-Lowering Agents and Dementia Risk: A\u00a0Systematic Review and Meta-Analysis. Jama Neurol Am Med Assoc. 2025; https:\/\/doi.org\/10.1001\/jamaneurol.2025.0360.","journal-title":"Jama Neurol Am Med Assoc"},{"key":"2665_CR117","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03438.x","author":"S Stafford","year":"2011","unstructured":"Stafford\u00a0S, Elahi\u00a0D, Meneilly\u00a0GS. Effect of the dipeptidyl peptidase\u20114 inhibitor sitagliptin in older adults with type\u00a02 diabetes mellitus. J\u00a0Am Geriatr Soc. 2011; https:\/\/doi.org\/10.1111\/j.1532-5415.2011.03438.x.","journal-title":"J Am Geriatr Soc"},{"key":"2665_CR118","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.568059","author":"N Barzilai","year":"2011","unstructured":"Barzilai\u00a0N, Guo\u00a0H, Mahoney\u00a0EM, Caporossi\u00a0S, Golm\u00a0GT, Langdon\u00a0RB, et\u00a0al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type\u00a02 diabetes: a\u00a0randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011; https:\/\/doi.org\/10.1185\/03007995.2011.568059.","journal-title":"Curr Med Res Opin"},{"key":"2665_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2010.10.003","author":"SL Schwartz","year":"2010","unstructured":"Schwartz\u00a0SL. Treatment of elderly patients with type\u00a02 diabetes mellitus: A\u00a0systematic review of the benefits and risks of dipeptidyl peptidase-4\u00a0inhibitors. Am J Geriatr Pharmacother. 2010; https:\/\/doi.org\/10.1016\/j.amjopharm.2010.10.003.","journal-title":"Am J Geriatr Pharmacother"},{"key":"2665_CR120","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2009.02484.x","author":"RE Pratley","year":"2009","unstructured":"Pratley\u00a0RE, McCall\u00a0T, Fleck\u00a0PR, Wilson\u00a0CA, Mekki\u00a0Q. Alogliptin use in elderly people: A\u00a0pooled analysis from phase\u00a02 and 3\u00a0studies. J\u00a0Am Geriatr Soc. 2009; https:\/\/doi.org\/10.1111\/j.1532-5415.2009.02484.x.","journal-title":"J Am Geriatr Soc"},{"key":"2665_CR121","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1035","author":"RA Defronzo","year":"2008","unstructured":"Defronzo\u00a0RA, Fleck\u00a0PR, Wilson\u00a0CA, Mekki\u00a0Q. Efficacy and safety of the dipeptidyl peptidase\u20114 inhibitor alogliptin in patients with type\u00a02 diabetes and inadequate glycemic control: A\u00a0randomized, double-blind, placebo-controlled study. Diabetes Care. 2008; https:\/\/doi.org\/10.2337\/dc08-1035.","journal-title":"Diabetes Care"},{"key":"2665_CR122","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01523.x","author":"AH Barnett","year":"2012","unstructured":"Barnett\u00a0AH. The role of GLP\u20111 mimetics and basal insulin analogues in type\u00a02 diabetes mellitus: Guidance from studies of liraglutide. Diabetes Obes Metab. 2012; https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01523.x.","journal-title":"Diabetes Obes Metab"},{"key":"2665_CR123","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01458.x","author":"U Graefe-Mody","year":"2011","unstructured":"Graefe-Mody\u00a0U, Friedrich\u00a0C, Port\u00a0A, Ring\u00a0A, Retlich\u00a0S, Heise\u00a0T, et\u00a0al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase\u20114 inhibitor linagliptin. Diabetes Obes Metab. 2011; https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01458.x.","journal-title":"Diabetes Obes Metab"},{"key":"2665_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9","author":"JA Dormandy","year":"2005","unstructured":"Dormandy\u00a0JA, Charbonnel\u00a0B, Eckland\u00a0DJA, Erdmann\u00a0E, Massi-Benedetti\u00a0M, Moules\u00a0IK, et\u00a0al. Secondary prevention of macrovascular events in patients with type\u00a02 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A\u00a0randomised controlled trial. Lancet. 2005; https:\/\/doi.org\/10.1016\/S0140-6736(05)67528-9.","journal-title":"Lancet"},{"key":"2665_CR125","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afp056","author":"AK Braun","year":"2009","unstructured":"Braun\u00a0AK, Kubiak\u00a0T, Kuntsche\u00a0J, Meier-H\u00f6fig\u00a0M, M\u00fcller\u00a0UA, Feucht\u00a0I, et\u00a0al. SGS: A\u00a0structured treatment and teaching programme for older patients with diabetes mellitus\u2014A prospective randomised controlled multi-centre trial. Age Ageing. 2009; https:\/\/doi.org\/10.1093\/ageing\/afp056.","journal-title":"Age Ageing"},{"key":"2665_CR126","doi-asserted-by":"crossref","unstructured":"Seidu S, Seewoodharry M, Longevity KK-TLH, 2021 undefined. De-intensification in older people with type\u00a02 diabetes: why, when and for whom? thelancet.com.","DOI":"10.1016\/S2666-7568(21)00204-X"},{"key":"2665_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00372-3","author":"M Munshi","year":"2025","unstructured":"Munshi\u00a0M, Kahkoska\u00a0AR, Neumiller\u00a0JJ, Alexopoulos\u00a0AS, Allen\u00a0NA, Cukierman-Yaffe\u00a0T, et\u00a0al. Realigning diabetes regimens in older adults: a\u00a04S Pathway to guide simplification and deprescribing strategies. Lancet Diabetes Endocrinol Elsevier Ltd. 2025; https:\/\/doi.org\/10.1016\/S2213-8587(24)00372-3.","journal-title":"Lancet Diabetes Endocrinol Elsevier Ltd"},{"key":"2665_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2012.04.012","author":"A Sinclair","year":"2012","unstructured":"Sinclair\u00a0A, Morley\u00a0JE, Rodriguez-Ma\u00f1as\u00a0L, Paolisso\u00a0G, Bayer\u00a0T, Zeyfang\u00a0A, et\u00a0al. Diabetes Mellitus in Older People: Position Statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J\u00a0Am Med Dir Assoc. 2012; https:\/\/doi.org\/10.1016\/j.jamda.2012.04.012.","journal-title":"J Am Med Dir Assoc"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02665-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02665-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02665-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:14:00Z","timestamp":1779315240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02665-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":128,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2665"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02665-w","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Huber hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Fortbildungsunterst\u00fctzung und\/oder Honorare f\u00fcr Vortr\u00e4ge und Beratung erhalten: Eli Lilly, Novartis, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Sanofi-Aventis, Merck Sharp & Dohme, Daiichi-Sankyo, Viatris. Zus\u00e4tzlich gibt J.\u00a0Huber an, dass f\u00fcr ihn pers\u00f6nlich kein Interessenkonflikt vorliegt. M.\u00a0Smeikal hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Fortbildungsunterst\u00fctzung und\/oder Honorare f\u00fcr Vortr\u00e4ge erhalten: Abbott, Eli Lilly, Novartis, Pfizer, Servier, Amgen, AstraZeneca, Sanofi-Aventis. Zus\u00e4tzlich gibt M.\u00a0Smeikal an, dass f\u00fcr ihn pers\u00f6nlich kein Interessenkonflikt vorliegt. C.H.\u00a0Saely hat von folgenden Firmen Honorare f\u00fcr Vortr\u00e4ge, Beratungst\u00e4tigkeit und Forschungsunterst\u00fctzung erhalten: Amgen, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Genericon, Genzyme, Merck, MSD, Novartis, Novo Nordisk, Omega Pharma, Pfizer, Sanofi. H.\u00a0Stingl hat von folgenden Unternehmen Unterst\u00fctzungen f\u00fcr Fortbildungen, Forschungsarbeit und\/oder Honorare f\u00fcr Vortr\u00e4ge oder Beratung erhalten: Eli Lilly, Novartis, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Sanofi-Aventis, Roche, MSD, Amgen, Abbott. Zus\u00e4tzlich gibt H.\u00a0Stingl an, dass f\u00fcr ihn pers\u00f6nlich kein Interessenkonflikt vorliegt. P.\u00a0Fasching hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare in den letzten 3\u00a0Jahren erhalten: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk und Sanofi. Zus\u00e4tzlich gibt P.\u00a0Fasching an, dass f\u00fcr ihn pers\u00f6nlich kein Interessenkonflikt vorliegt. Er legt offen, dass er in diesem Zeitraum von den genannten Firmen Honorare f\u00fcr Vortr\u00e4ge und Consulting erhalten bzw. Fortbildungsunterst\u00fctzung im Rahmen der (dienst)rechtlichen Rahmenbedingungen bezogen hat (Einladung zu Kongressen) bzw. klinische Studien als PI mit einzelnen Firmen durchgef\u00fchrt hat bzw. durchf\u00fchrt. M.\u00a0Lechleitner gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}